Delivery Order SPE2DB22D2214-SPE2DB25FS5VK
- Not listed
- This is a $37,654.78 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 MG TABLET UU 30S, a pharmaceutical product. The contract has a completion date of September 23, 2024. AmerisourceBergen, a major pharmaceutical distributor, is the prime contractor for this order, which is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at up to $999,999,999 through...
- This $71,221.86 firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation's Corporate Office Division. The contract is for the supply of BIKTARVY 50-200-25 MG TABLET, a pharmaceutical product, to support the healthcare needs of military personnel, veterans, and other federal beneficiaries. AmerisourceBergen, a major pharmaceutical distributor, holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
- The Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a firm fixed price delivery order worth $14,498.17 to supply BIKTARVY 50-200-25 MG TABLET in Conshohocken, Pennsylvania. This delivery order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded by DLA to Amerisourcebergen Drug Corp as the sole prime contractor. The IDC enables Amerisourcebergen to deliver a comprehensive...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical distribution company. The contract, with a potential value of $39,088.72, is for the delivery of BIKTARVY 50-200-25 MG TABLET in 30-count packages. This delivery order is part of a larger indefinite delivery contract (IDC) between DLA and Amerisourcebergen Drug Corp,...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The contract, valued at $15,672.81, is for the provision of BIKTARVY 50-200-25 MG TABLET UU 30S, a pharmaceutical product. This delivery order is placed under a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide BIKTARVY 50-200-25 MG TABLET in 30-count units. The $49,047.50 contract has an ultimate completion date of April 12, 2024. AmerisourceBergen Drug Corp holds an indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver...
- This contract was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $46,043.27 firm fixed-price delivery order is for the supply of BIKTARVY 50-200-25 MG TABLET UU 30S, a pharmaceutical product. The contract has an ultimate completion date of November 3, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $9,201.84 to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The contract is for the provision of BIKTARVY 50-200-25 MG TABLET UU 30S, a pharmaceutical product, with a completion date of February 22, 2024. This delivery order is issued under Amerisourcebergen Drug Corp's existing indefinite delivery contract with DLA, valued at up to...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $18,447.60 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide BIKTARVY 50-200-25 MG TABLET UU 30S pharmaceuticals. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a period of performance through December 31, 2025. The IDC serves as the primary...
- This $8,555.11 firm fixed-price delivery order contract was awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of BIKTARVY 50-200-25 MG TABLET UU 30S, a prescription medication. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary...
- SPE2DB22D2214Indefinite Delivery Contract
- SPE2DB22D2214-SPE2DB25FS5VKDelivery Order
The Defense Logistics Agency awarded a delivery order totaling $40,340.72 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets (30-count units). This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025, and represents a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor and healthcare solutions provider supporting federal medical procurement needs across military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The prime contract serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The company's federal contract portfolio demonstrates extensive experience fulfilling diverse pharmaceutical requirements across multiple therapeutic domains through open competition, positioning it as a primary vendor within the DLA's Medical Supply Chain network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $40.3k | 7/18/25 |